MurrayCJLopezAD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease study. Lancet1997;349:1436–42.
2.
HienTTWhiteNJ. Qinghaosu. Lancet1993;341:603–8.
3.
Centers for Disease Control and Prevention. Specific recommendations for vaccinations and prophylaxis. Malaria. In: Health information for international travel 1996–97. Atlanta: US Department of Health and Human Services, 1997:128–36.
4.
BradleyDJWarhurstDC. Guidelines for the prevention of malaria in travellers from the United Kingdom. Commun Dis Rep CDR Rev1997;7:R137–52.
5.
LellBLucknerDNdjaveMScottTKremsnerPG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet1998;351:709–13.
6.
FryauffDJBairdJKBasriHSumawintaIPurnomoRichieTLRandomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet1995;346:1190–3.
7.
AndersenSLOlooAJRagamaOBAlemanGMBermanJDTangDBSuccessful double-blind randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in Western Kenya. Clin Infect Dis1998;26:146–50.
8.
SteffenR. Travel medicine — Prevention based on epidemiological data. Trans R Soc Trop Med Hyg1991;85:156–62.
9.
OostweegelLMMBeijnenJHMulderJW. Hepatitis during chloroguanide prophylaxis. Ann Pharmacother1998;32:1023–5.
10.
CroftAMJGarnerP. Mefloquine to prevent malaria in non-immune adults. Cochrane Library1997;3:1–14.
11.
NostenFter KuileFOLuxembergerCWoodrowCKyleDEChongsuphajaisiddhiTCardiac effects of antimalarial treatment with halofantrine. Lancet1993;341:1054–6.
12.
DavisTMEDemboLGKaye-EddieSAHewittBJHislopRGBattyKT. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: A double-blind, placebo-controlled trial. Br J Clin Pharmacol1996;43:415–21.
13.
HandysidesSE. Rise in falciparum malaria imported from east Africa. Eurosurveillance Wkly1998;(14 May):2–3.
